Procurement Summary
Country: USA
Summary: synthesis and distribution of drugs of abuse and related compounds
Deadline: 21 Feb 2026
Posting Date: 07 Feb 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 135293404
Document Ref. No.: 75N95022D00016SB
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
NOTICE OF A PROPOSED CONTRACT ACTION
NON-COMPETITIVE
INTRODUCTION
PURSUANT TO FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A NOTICE OF A PROPOSED CONTRACT ACTION.
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022D00016 WITH RESEARCH TRIANGLE INSTITUTE.
The National Institute on Drug Abuse (NIDA) Division of Therapeutics and Medical Consequences (DTMC) at the National Institutes of Health (NIH) intends to modify the Single Award Indefinite Delivery, Indefinite Quantity (IDIQ) Contract No. 75N95022D00016 “Synthesis and Distribution of Drugs of Abuse and Related Compounds” to increase the Single Award IDIQ maximum by $3, 718, 289 from $14, 004, 330 to $17, 722, 619 during the five (5) year ordering period from June 9, 2022 to June 8, 2027; there are no other changes.
The increase to the IDIQ maximum will allow for the continuation of work begun under the Synthesis and Distribution of Drugs of Abuse and Related Compounds contract and prevent any delays or disruption of support services for scientific research working on problems of substance use and drug dependence with authentic and pure supplies of controlled drugs and research chemicals essential for ongoing and upcoming pre-clinical and clinical trials while a new contract is properly planned and competed. To support efforts in addressing the national public health crisis from substance use, NIDA through this contract modification also addresses an increased need for drug product to support clinical trials. The increase in the IDIQ maximum will, therefore, allow for the continuation of work initiated under this contract in addition to purchasing drug product to support new and ongoing clinical trials.
The contract provides contract support services in the following areas to:
Produce and distribute labeled and unlabeled drugs of abuse and other research compounds to researchers as approved by the NIDA COR;
Analyze, test, and maintain ...
Notice ID: 75n95022d00016sb
Department/Ind. Agency: health and human services, department of
Original Set Aside: total small business set-aside (far 19.5)
Sub-tier: national institutes of health
Office: national institutes of health nida
Product Service Code: an11 - health r&d services; health care services; basic research
NAICS Code: 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Inactive Dates: mar 08, 2026
Inactive Policy: 15 days after response date
Documents
Tender Notice